Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes
- Resource Type
- Authors
- Gregory G. Schwartz; Peter Ganz; David D. Waters; Steven R. Arikian
- Source
- The American Journal of Cardiology. 92:1109-1112
- Subject
- medicine.medical_specialty
Acute coronary syndrome
Cost-Benefit Analysis
Atorvastatin
Myocardial Infarction
Myocardial Ischemia
Ischemia
MIRACL
Placebo
health services administration
Internal medicine
Secondary Prevention
Humans
Medicine
Pyrroles
heterocyclic compounds
Angina, Unstable
Economics, Pharmaceutical
cardiovascular diseases
business.industry
Vascular disease
nutritional and metabolic diseases
Health Care Costs
Syndrome
Direct cost
medicine.disease
Heptanoic Acids
Acute Disease
Circulatory system
Cardiology
lipids (amino acids, peptides, and proteins)
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiology and Cardiovascular Medicine
business
medicine.drug
- Language
- ISSN
- 0002-9149
An economic analysis was conducted using clinical outcomes in the MIRACL trial that evaluated high-dose atorvastatin versus placebo for 16 weeks after acute coronary syndrome. The direct cost of atorvastatin was largely offset by the associated decrease in cardiovascular events. The net incremental cost of atorvastatin treatment was 157 dollars/patient with a cost-effectiveness ratio of 4,086 dollars/event avoided.